Aroa Biosurgery Reports FY26 Results and FY27 Outlook
Key points
- FY26 total revenue of NZ$103.9 million, 23% growth on FY25
- Product gross margin of 85.5%, normalized EBITDA of NZ$12.6 million
- FY27 revenue guidance of NZ$115-125 million, normalized EBITDA of NZ$8-11 million
Full summary
Aroa Biosurgery Limited, a soft tissue regeneration company, has announced its full-year results for FY26, showing a total revenue of NZ$103.9 million, a 23% increase from the previous year. The company reported a product gross margin of 85.5% and normalized EBITDA of NZ$12.6 million. Aroa Biosurgery also provided guidance for FY27, expecting total revenue to range between NZ$115-125 million and normalized EBITDA to be between NZ$8-11 million. The company anticipates continued growth in its Myriad product line and the potential market opportunity for its Symphony product.
Guidance
FY27 revenue guidance of NZ$115-125 million, normalized EBITDA of NZ$8-11 million
Outlook
Aroa Biosurgery expects continued growth in its Myriad product line and sees a significant market opportunity for its Symphony product in FY27.
Summary generated by a large language model. Please interpret with care.